Orphapacket:
  AverageAgeOfOnsets:
    AverageAgeOfOnset:
    - value: All ages
  DisorderType:
    PURL: http://www.orpha.net/ORDO/Orphanet_377788
    value: Disease
  ExternalReferences:
  - ExternalReference:
      DisorderMappingRelation: BTNT (ORPHAcode is broader than the targeted code used
        to represent it)
      Reference: '161550'
      Source: OMIM
  - ExternalReference:
      DisorderMappingRelation: 'E (Exact mapping: the two concepts are equivalent)'
      Reference: '607107'
      Source: OMIM
  - ExternalReference:
      DisorderMappingRelation: BTNT (ORPHAcode is broader than the targeted code used
        to represent it)
      Reference: '617075'
      Source: OMIM
  Genes:
  - Gene:
      DisorderGeneAssociationType: Disease-causing somatic mutation(s) in
      ExternalReferences: []
      Name: NFKB inhibitor alpha
      Symbol: NFKBIA
  Label: Nasopharyngeal carcinoma
  ORPHAcode: '150'
  ORPHApacketId: '150'
  PURL: http://www.orpha.net/ORDO/Orphanet_150
  Parents:
  - Parent:
    - Label: Epstein-Barr Virus-associated carcinoma
      ORPHAcode: '289651'
  - Parent:
    - Label: Rare respiratory tumor
      ORPHAcode: '98060'
  - Parent:
    - Label: Rare otorhinolaryngologic tumor
      ORPHAcode: '98061'
  - Parent:
    - Label: Pediatric respiratory cancer
      ORPHAcode: '602691'
  - Parent:
    - Label: Epstein-Barr Virus-related cancer
      ORPHAcode: '602713'
  - Parent:
    - Label: Pediatric head and neck cancer
      ORPHAcode: '602715'
  Prevalences:
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: China
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: 8061578[PMID]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: Unknown
      PrevalenceGeographic: Worldwide
      PrevalenceQualification: Class only
      PrevalenceType: Point prevalence
      Source: ORPHANET
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Europe
      PrevalenceQualification: Value and class
      PrevalenceType: Point prevalence
      Source: European Medicines Agency 2015[INST]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Europe
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]_28687376[PMID]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Austria
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Belgium
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Bulgaria
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Croatia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Czech Republic
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Estonia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Finland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Germany
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Iceland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Ireland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Italy
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Latvia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Lithuania
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Norway
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Poland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Portugal
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Slovakia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Slovenia
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Spain
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Switzerland
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: Netherlands
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 1 000 000
      PrevalenceGeographic: United Kingdom
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  - Prevalence:
      PrevalenceClass: 1-9 / 100 000
      PrevalenceGeographic: Malta
      PrevalenceQualification: Value and class
      PrevalenceType: Annual incidence
      Source: RARECARE surveillance of rare cancers in Europe[REG]
      ValMoy: no data
  Synonyms:
  - Synonym: NCP
  - Synonym: Squamous cell carcinoma of the nasopharynx
  TextSection:
    Contents: Nasopharyngeal carcinoma (NPC) is a tumor arising from the epithelial
      cells that cover the surface and line the nasopharynx.
    TextSectionType: Definition
  TypeOfInheritances:
  - TypeOfInheritance:
      value: Multigenic/multifactorial
  - TypeOfInheritance:
      value: Not applicable
  copyright: Orphanet (c) 2024
  creationDate: '2024-12-03 10:13:55'
  version: 1.3.29 / 4.1.7 [2023-08-02] (orientdb version)
